Skip to content

French HIV-2 cohort study: treat only when plasma viral load can be measured.

HIV patients with severe immune damage have incomplete immune recovery - but does it matter?

More evidence that earlier treatment provides greatest benefit for children with HIV

Better clinical outcomes if HAART started before CD4 cell count falls below 200

Landmark study shows why AZT/3TC/efavirenz now preferred as first-line HIV treatment

Abacavir leads to better CD4 increase than AZT when combined with 3TC and EFV

Nevirapine-based fixed-dose combination ARVs

Once daily head to head shows efavirenz still top

Treatment after seroconversion becoming more common